LOS ANGELES, CA--(Marketwire - Jan 14, 2013) - CompuMed, Inc. (
Also effective December 31, 2012, W. Scott Rombach, in addition to his responsibilities as President, assumed the CEO role. "Scott's expertise in driving global enterprise transactions and developing strategic partnerships is a tremendous asset to CompuMed. He has a unique skill set and is the right individual to take the company to the next level," said Maurizio Vecchione.
Mr. Rombach has served on the Board of Directors of CompuMed since 2011. He was appointed President in October of 2012.
As a sales executive with PeopleSoft, Inc., Mr. Rombach specialized in executing large software and services deals. He brings a deep understanding of how customers can best leverage enterprise technology solutions to cut costs and drive revenue. Prior to its acquisition by Oracle, PeopleSoft was the global leader in providing enterprise human resources and payroll software solutions. Mr. Rombach also has experience in a start-up environment. With Armstrong Laing, he drove sales that helped this UK based company to become one of the market leaders in Activity Based Management (ABM) software solutions. Mr. Rombach has an M.B.A. from Georgia State University and a B.A. in Marketing from Michigan State University.
"We are very grateful for the contributions Maurizio has made to the company and are glad that he will continue to serve on the board. The board feels that the company is in good hands with Scott Rombach as its leader," said Mr. Mark Stolper, CompuMed's Chairman.
CompuMed's diagnostic and management tools for the healthcare community focus on telecardiology systems and software solutions. We offer analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed at www.compumed.net and follow on Twitter @compumed.
Statements contained in this report, such as statements about revenue, operations, and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission and OTC Pink operated by OTC Markets. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.